Overview
Research Background: According to the Myasthenia Gravis Foundation of America (MGFA, 2015), the estimated prevalence of myasthenia gravis is 14-20 per 100,000 people, with a higher prevalence in young female individuals compared to males. However, as individuals age, especially after the age of 50, the prevalence in males becomes higher than in females. myasthenia gravis patients often experience varying degrees of disability, leading to the need for long-term medical care, medication, and lifestyle adjustments. This also gives rise to subsequent challenges in caregiving, affecting both the patients' families and society.
Description
:This study aims to assess the effectiveness of using a combination of traditional Chinese and Western medicine,to improve the meridian energy and autonomic nervous system function of myasthenia gravis patients.
Eligibility
Inclusion Criteria:
- Patients diagnosed with ocular myasthenia by a doctor
- Western medicine prescriptions only take oral Mestinon (Pyrido stigmine Bromide)
- Patients over 20 years old
- Can understand and understand Those who can speak Mandarin or Taiwanese
- those with a clear state of consciousness and no diagnosis of mental illness
- patients and their families who are willing to receive precise integrated treatment of traditional Chinese and Western medicine.
Exclusion Criteria:
- Patients with liver failure or kidney failure
- Allergy symptoms to traditional Chinese medicine, such as skin itching and redness
- Patients with malignant tumors
- Patients currently undergoing radiotherapy and chemotherapy
- Pregnant
- Cardiac rhythm device implementer